Delving into the Latest Updates on Gastrin synthetic peptide antigen vaccine(Pepscan Systems BV) with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide vaccine, Therapeutic vaccine

Synonyms-

Target

GAST

Mechanism

Gastrin-17 inhibitors(Gastrin 17 inhibitors), Immunostimulants

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [1]

Active Indication-

Inactive Indication

Pancreatic CancerZollinger-Ellison Syndrome

Originator Organization

Pepscan Systems BV

Active Organization-

Inactive Organization

Immunovo BVPepscan Systems BV

Drug Highest PhasePendingPreclinical

First Approval Date-

Regulation-

The current pandemic called COVID-19 caused by the SARS-CoV-2 virus brought the need for the search for fast alternatives to both control and fight the SARS-CoV-2 infection. Therefore, a race for a vaccine against COVID-19 took place, and some vaccines have been approved for emergency use in several countries in a record time. Ongoing prophylactic research has sought faster, safer, and precise alternatives by redirecting knowledge of other vaccines, and/or the development of new strategies using available tools, mainly in the areas of genomics and bioinformatics. The current review highlights the development of synthetic antigen vaccines, focusing on the usage of bioinformatics tools for the selection and construction of antigens on the different vaccine constructions under development, as well as strategies to optimize vaccines for COVID-19.

100 Deals associated with Gastrin synthetic peptide antigen vaccine(Pepscan Systems BV)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pancreatic Cancer	Preclinical	-	Pepscan Systems BV	-
Pancreatic Cancer	Preclinical	-	Immunovo BV	-
Zollinger-Ellison Syndrome	Preclinical	-	Pepscan Systems BV	-
Zollinger-Ellison Syndrome	Preclinical	-	Immunovo BV	-